BioCatalystWatch
LEGNWorkspace / LEGN / OverviewCompany library
Price
Market cap
Next catalystDec 12, 2026CARVYKTI — CARTITUDE-4 · Phase 3 dataCompany release ↗
Cash

Chart & Events

Candle interval

Core Clinical

CARVYKTI

BCMA

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

CARVYKTI

BCMA

Upcoming / outlook

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

CARVYKTI

BCMA

Upcoming / outlook

CARVYKTI

BCMA

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

Other pipelines

LB1908

Claudin 18.2

PreINDP1P2P3FilingApproved
CARVYKTI

BCMA

PreINDP1P2P3FilingApproved
LB2501

CD19 × CD20 × CD3

PreINDP1P3FilingApproved
Upcoming / outlook

Partner / License out

DLL3

PreINDP1P2P3FilingApproved

Approved / commercial

CARVYKTI

BCMA

PreINDP1P2P3FilingApproved
CARVYKTI

History / paused

PreINDP1P2P3FilingApproved

Financial position

Cash and cash equivalents

Source and basis

Short-term investments

Source and basis

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Source and basis

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

LEGN PR & News

PR & News

LEGN SEC archive